Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Breast Cancer Recurrence DNA Assay In Development; Exagen Targets HCV

This article was originally published in The Gray Sheet

Executive Summary

Exagen Diagnostics is working with FDA to design a pivotal trial assessing whether results from an earlier study of the firm's breast cancer recurrence genomic test can be duplicated in a larger cohort

You may also be interested in...



Exagen Files First Of Six Planned 510(k)s For Genomic Test Kits

Exagen Diagnostics recently filed the first of six planned 510(k) applications for test kits developed using its novel Coperna computational platform, kicking off a major push into the nascent genomic test kit market

Exagen Files First Of Six Planned 510(k)s For Genomic Test Kits

Exagen Diagnostics recently filed the first of six planned 510(k) applications for test kits developed using its novel Coperna computational platform, kicking off a major push into the nascent genomic test kit market

FDA Approves Another Chemotherapy Assay, First Monoclonal Her-2/neu Test

BioGenex's February launch of its InSite Her-2/neu monoclonal antibody kit for breast cancer detection will be supported by 12 U.S. sales reps

Related Content

UsernamePublicRestriction

Register

MT021401

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel